Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R2

VEGF R2

Brief Information

Name:Vascular endothelial growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,VEGFR2,KDR,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1,Kinase insert domain receptor,Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase),Protein-Tyrosine Kinase Receptor Flk-1,FLK1,Tyrosine Kinase Growth Factor Receptor,Fetal Liver Kinase-1,Soluble VEGFR2,CD309 Antigen,EC 2.7.10.1,VEGFR-2,CD309,VEGFR,FLK-1,Vascular Endothelial Growth Factor Receptor-2
Number of Launched Drugs:15
Number of Drugs in Clinical Trials:47
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

KDR-HP227-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-VEGFR2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human VEGF R2, His Tag (Cat. No. KDR-HP227) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CHEK-ATF044-Cell-based assay
 VEGF R2 FACS

Expression analysis of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on VEGFR2 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-VEGFR2 antibody.

VE2-M5258-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

KDR-H82E5-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

KDR,CD309,FLK1,VEGFR,VEGFR2

Background

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and  is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda United States Carcinoma, Renal Cell Aveo Pharmaceuticals Inc 2017-08-24 Carcinoma, Renal Cell Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Macau Colorectal Neoplasms Hutchison Huangpu Medicine (Shanghai) Co Ltd 2018-09-04 Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Rectal Neoplasms; Neoplasms; Colonic Neoplasms; Kidney Diseases; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc Nexavar, 多吉美 EU Thyroid Neoplasms Bayer AG 2005-12-01 Lung Neoplasms; Adrenocortical Carcinoma; Mesothelioma; Breast Neoplasms; Hepatitis B; Prostatic Neoplasms; Brain Neoplasms; Sarcoma; Pulmonary Arterial Hypertension; Medullary thyroid cancer (MTC); Hepatitis C; Thyroid Neoplasms; Leukemia, Monocytic, Acute; Lymphoma, T-Cell; Digestive System Neoplasms; Leukemia, Myeloid, Acute; Glioma; Venous Thrombosis; Facial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Adenocarcinoma; Fasting; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms; Ovarian Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Kidney Neoplasms; Recurrence; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Abdominal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Kidney Diseases; Myelodysplastic Syndromes; Myeloproliferative Disorders; Thyroid Details
Vandetanib AZD-6474; CH-331; ZD-6474 Approved Astrazeneca Pharmaceutical Co Ltd Zactima, Caprelsa Japan Medullary thyroid cancer (MTC) Astrazeneca Pharmaceutical Co Ltd 2011-04-06 Thyroid Neoplasms; Paraganglioma; Adenocarcinoma; Precancerous Conditions; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Neuroendocrine; Solid tumours; Colorectal Neoplasms; Pleural Effusion; Prostatic Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); Multiple Myeloma; Mesothelioma; Pheochromocytoma; Stomach Neoplasms; Esophageal Neoplasms Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Urogenital Neoplasms; Prostatic Neoplasms; Osteosarcoma; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Carcinoma, Small Cell; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Fallopian Tube Neoplasms; Thyroid Neoplasms; Lung Neoplasms; Breast Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Macular Degeneration; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Thyroid Cancer, Papillary; Neoplasms, Germ Cell and Embryonal; Neoplasms; Ovarian Neoplasms; Solid tumours; Chondrosarcoma; Epistaxis; Telangiectasia, Hereditary Hemorrhagic; Leiomyosarcoma; Carcinoma, Renal Cell; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Head and Neck Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Pancreatic Neoplasms; Dermatofibrosarcoma; Central Nervous System Neoplasms; Lymphedema; Liposarcoma; Adenocarcinoma, Follicular; Soft Tissue Neoplasms; Sarcoma Details
Ripretinib DCC-2618 Approved Deciphera 擎乐, Qinlock United Kingdom Gastrointestinal Stromal Tumors Deciphera Pharmaceuticals Llc 2020-05-15 Neoplasms; Mastocytosis, Systemic; Gastrointestinal Stromal Tumors Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Adenoid Cystic; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Solid tumours; Glucagonoma; Multiple Myeloma; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Glioblastoma; Colonic Neoplasms; Hemangiosarcoma; Carcinoma, Islet Cell; Insulinoma; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Axitinib AG-013736; CLS-AX; AG-13736; PF-01367866 Approved Pfizer Pharmaceuticals Ltd (China) Inlyta, 英立达 Mainland China Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Endometriosis; Macular Degeneration; Paraganglioma; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Sarcoma; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Solid tumours; Multiple Myeloma; Mesothelioma; Adrenal Cortex Neoplasms; Nasopharyngeal Neoplasms; Glioblastoma; Myelodysplastic Syndromes; Skin Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Renal Cell; Ovarian Neoplasms; Kidney Neoplasms Details
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Apatinib Mesylate YN-968D1 Approved Advenchen Laboratories 艾坦, Aitan Mainland China Stomach Neoplasms Jiangsu shengdi Medicine Co Ltd 2014-10-17 Esophageal Squamous Cell Carcinoma; Metaplasia; Breast Neoplasms; Sarcoma; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Neuroblastoma; Bone Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Thyroid Neoplasms; Radiation Injuries; Lymphoma, T-Cell; Lung Neoplasms; Fallopian Tube Neoplasms; Glioma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Rhabdomyosarcoma; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Nasopharyngeal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Adenoid Cystic; Soft Tissue Neoplasms; Liver Diseases Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Genital Neoplasms, Female; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Oligodendroglioma; Bronchitis; Silicosis; Gliosarcoma; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Idiopathic Pulmonary Fibrosis; Head and Neck Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Bronchiolitis Obliterans; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rejection of lung transplantation; Carcinoma, Renal Cell; Scleroderma, Systemic; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Glioblastoma; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis Details
Ramucirumab IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 Approved Dyax Pharma Cyramza Mainland China Stomach Neoplasms Lilly Suzhou Pharmaceutical Co Ltd 2014-04-21 Peritoneal Neoplasms; Breast Neoplasms; Lymphoma, Mantle-Cell; Prostatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Ureteral Neoplasms; Colorectal Neoplasms; Urethral Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Melanoma; Carcinoid Tumor; Biliary Tract Neoplasms; Skin Melanoma; Liver Neoplasms; Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Microsatellite instability-high cancer; Urinary Bladder Neoplasms Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Carcinoma, Adenoid Cystic; Thrombosis; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Lymphoma; Thyroid Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Neuroendocrine Tumors; Solid tumours; Urinary Bladder Neoplasms; Adenocarcinoma, Follicular; Liver Diseases; Small Cell Lung Carcinoma; Neoplasms; Kidney Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Thyroid Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Bile Duct Diseases; Bone Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Medullary thyroid cancer (MTC); Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Esophageal Diseases; Paraganglioma; Adenocarcinoma; Osteoma; Gastrointestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leiomyosarcoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Liver Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Genital Diseases, Female; Stomach Neoplasms; Pheochromocytoma; Digestive System Diseases; Gastrointestinal Diseases; Ovarian Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Tripl Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt Approved Pfizer Pharmaceuticals Ltd (China) 索坦, Sutent Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Diabetic macular oedema; Thyroid Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Peritoneal Neoplasms; Astrocytoma; Thymus Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Thymoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Adrenocortical Carcinoma; Adenocarcinoma; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Retinal Vein Occlusion; Meningioma; von Hippel-Lindau Disease; Neoplasm Metastasis; Macular Degeneration; Carcinoma, Hepatocellular; Adenocarcinoma, Follicular; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Neoplasms, Gonadal Tissue; Nervous System Neoplasms; Germinoma; Brain metastases; Hemangiopericytoma; Urogenital Neoplasms; Hemangioblastoma; Glioblastoma; Pheochromocytoma; Pelvic Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Islet Cell; Histiocytom Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
PZ-1 PZ-1 Phase 1 Clinical Chongqing University Of Arts And Sciences Solid tumours Details
Pamufetinib TAS-115 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Neoplasms Details
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) Phase 1 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AVI-3207 AVI-3207 Phase 1 Clinical Avixgen Macular Degeneration Details
VEGFR2 peptide vaccine (Tokyo University) Phase 1 Clinical University Of Tokyo Pancreatic Neoplasms Details
Sorafenib Tosylate/MG-K10 MG-D-1609 Phase 2 Clinical Metagone Biotech Solid tumours Details
RA1115-B1 RA1115-B1 Phase 1 Clinical Wet Macular Degeneration Details
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) BC-001 Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd Solid tumours Details
FNX-006 FNX-006 Phase 1 Clinical Sichuan University, Chengdu Fannuoxi Biomedical Technology Co Ltd Triple Negative Breast Neoplasms; Melanoma Details
SYHA-1817 SYHA-1817 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell Details
JI-101 JI-101; CGI-1842 Gilead Sciences Inc, Jubilant Innovation Details
Ilorasertib ABT-348; A-9686600; Abbott-968660 Abbvie Inc Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
Motesanib Diphosphate AMG-706 Amgen Inc Details
AEE-788 AEE-788; NVP-AEE-788 Novartis Pharma Ag Details
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X Phase 2 Clinical Sanofi Prostatic Neoplasms Details
BMS-690514 BMS-690514 Bristol-Myers Squibb Company Details
PAN-90806 CP-632; OSI-632; CP-547632; PAN-90806 Pfizer Inc, Osi Pharmaceutical Details
PF-337210 PF-337210; PF-00337210 Pfizer Inc Details
KDR2-2 Phase 2 Clinical Guangzhou Huiborui Biomedical Technology Co Ltd Glaucoma, Neovascular; Corneal Neovascularization Details
LM-061 LM-061 Phase 1 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Solid tumours Details
Gersizangitide AXT-107 AsclepiX Therapeutics Inc Details
Alacizumab pegol CDP-791 Ucb Details
Gentuximab Genescience Pharmaceuticals Co Ltd Details
BR-55 BR-55; BR55 CEUS Phase 2 Clinical Sonus Pharmaceuticals Neoplasms; Contrast agents; Diagnostic agents; Inflammation Details
Orantinib TSU-68; SU-6668; SU-006668 Pfizer Inc Details
Vatalanib succinate ZK-222584; CGP-79787D; PTK-787 Novartis Pharma Ag Details
SU-014813 SU-14813; SU-014813 Pfizer Pharmaceuticals Ltd (China) Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Deciphera Details
AG-13958 AG-13958; AG-013958 Pfizer Inc Details
Olinvacimab SSS-23; TTAC-0001 Pharmabcine Details
Cediranib AZD2171; AZD-2171; NSC-732208 Astrazeneca Plc Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasm Metastasis Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Mirati Therapeutics Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 1 Clinical Arqule Inc Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms Details
RAF-265 RAF-265; CHIR-265 Chiron Corp, Novartis Pharma Ag Details
CYC-116 CYC-116 Cyclacel Pharmaceuticals Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer AG Solid tumours; Stomach Neoplasms Details
VEGFR2 peptide vaccine (VAXIMM) VXM-01 Merck Serono Details
EDP317 ACTB-1003; EOC-317; EDP-317 Phase 1 Clinical Bayer AG, Act Biotech Inc Biliary Tract Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms Details
ODM-203 ODM-203 Orion Corp Details
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) Phase 3 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Simmitinib hydrochloride SOMCL-15-290 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
Semaxanib TSU-16; SU-5416; NSC-696819 Pfizer Inc Details
Veglin AS-3; VEGF-AS University Of Southern California Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 1 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Pulocimab AK-109 Phase 2 Clinical Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
Sorafenib/MG-005 MGD-1509; MG-D-1509 Metagone Biotech, Tri-Service General Hospital Details
JY-025 JY-025 Phase 2 Clinical Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Neoplasms Details
Ramucirumab biosimilar (Henlius) HLX-12 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd Solid tumours Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Cholangiocarcinoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Thyroid Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Nasopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Carcinoma, Renal Cell; Solid tumours; Biliary Tract Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Sitravatinib IND-155305; MG-516; MG-91516; MGCD-516 Phase 3 Clinical Mirati Therapeutics Ureteral Neoplasms; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Hepatic Insufficiency; Solid tumours; Breast Neoplasms; Liposarcoma; Lung Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms Details
MSB-0254 MSB-0254 Phase 1 Clinical Mabspace Biosciences Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message